Cover Story
Guest Editorial
Over and over again, I’ve seen the same missteps, clumsy excuses, and faulty logic during sponsor presentations to the FDA Oncologic Drugs Advisory Committee, repeated as if part of a tragic, regulatory update to the movie Groundhog Day.
In Brief
Clinical Roundup
Drugs & Targets
Trending Stories
- Moving from mandate to mission: Community outreach and engagement at NCI-designated cancer centers
“COE is broken.” - Art exhibit at University of Miami Sylvester bridges North and South America
- Don’t confirm RFK Jr. for HHS, 77 Nobel laureates urge the Senate
- The Human Tumor Atlas Network charts the roadmap for advancing spatial omics
- VCU awarded $9M from NCI to establish Cancer Control Equity Research Center
- The Cancer Letter’s most-read stories of 2024